Table 2.

OCT* characteristics of single-agent vs multi-agent anti-VEGF therapy

Anti-VEGF Drug for Single-agent Monotherapy	# SRF + Pre-treatment	# SRF + Post-treatment	P -value	# IRF + Pre-treatment	# IRF + Post-treatment	P -value
Bevacizumab ( N = 19)	14	2	P $<$ 0.01	8	2	P = 0.077
Ranibizumab ( N = 71)	42	8	P $<$ 0.001	43	16	P $<$ 0.001
Aflibercept ( N = 47)	30	1	P $<$ 0.001	27	10	P $<$ 0.001
Multi-agent Therapy ( N = 87)	73	24	P $<$ 0.001	28	14	P $<$ 0.001
Total Cohort ( N = 224)	159	35	P $<$ 0.001	106	42	P $<$ 0.001
OCT, optical coherence tomography; SRF, subretinal fluid; IRF, intraretinal fluid; VEGF, vascular endothelial growth factor